Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | HTR2B | P41595 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17086789 | 1.00 | HTR2C (0.50) | HTR2CCHRM2CHRM4CHRM5ACHE | |
| SCHEMBL20432699 | 1.00 | HTR2C (0.50) | HTR2CCHRM2CHRM4CHRM5ACHE | |
| SCHEMBL1310132 | 1.00 | HTR2C (0.50) | HTR2CCHRM2CHRM4CHRM5ACHE | |
| SCHEMBL20432698 | 1.00 | HTR2C (0.50) | HTR2CCHRM2CHRM4CHRM5ACHE | |
| Hydrochloric Acid SCHEMBL3155670 | 0.98 | CHRM2 (0.53) | HTR2CCHRM2CHRM4CHRM5ACHE | |
| Hydrochloric Acid SCHEMBL3155675 | 0.98 | CHRM2 (0.53) | HTR2CCHRM2CHRM4CHRM5ACHE | |
| SCHEMBL20797832 | 0.82 | CHRM2 (0.55) | CHRM2CHRM4CHRM5ACHESIGMAR1 | |
| SCHEMBL20811168 | 0.82 | CHRM2 (0.55) | CHRM2CHRM4CHRM5ACHESIGMAR1 | |
| SCHEMBL10077401 | 0.82 | ACHE (0.55) | CHRM2CHRM4CHRM5ACHESIGMAR1 | |
| SCHEMBL11144165 | 0.82 | ACHE (0.55) | CHRM2CHRM4CHRM5ACHESIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106232584-B | As 6 inhibitor of histone deacetylase new compound and include its pharmaceutical composition | 株式会社钟根堂 | 2019-06-28 | — | — | CN | disclosed |
| EP-3331864-A2 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2018-06-13 | — | — | EP | disclosed |
| US-9828393-B2 | Silylalkyloxyaryl compounds and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2017-11-28 | — | — | US | disclosed |
| CN-106232584-A | As the new compound of histone deacetylase 6 inhibitor and the pharmaceutical composition comprising it | 株式会社钟根堂 | 2016-12-14 | — | — | CN | disclosed |
| WO-2016138114-A1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20160159832-A1 | SILYLALKYLOXYARYL COMPOUNDS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2016-06-09 | — | — | US | disclosed |
| US-8575170-B2 | Flurbiprofen analogs and methods of use in treating cancer | THE REGENTS OF THE UNVERSITY OF COLORADO, A BODY CORPORATE (US) | 2013-11-05 | — | — | US | disclosed |
| US-20110275648-A1 | FLURBIPROFEN ANALOGS AND METHODS OF USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2011-11-10 | — | — | US | disclosed |
| US-7858349-B2 | Anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2010-12-28 | — | — | US | disclosed |
| WO-2010127381-A1 | DIAGNOSIS, MONITORING, PROGNOSIS, PREVENTION AND TREATMENT OF ANEURYSMS | JAMES COOK UNIVERSITY (AU) | 2010-11-11 | — | — | WO | disclosed |
| US-20050054850-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2005-03-10 | — | — | US | disclosed |
| US-20040176388-A1 | Piperazine derivatives as 5-HT1B antagonists | SMITHKLINE BEECHAM P.I.C. | 2004-09-09 | — | — | US | disclosed |
| US-20040132720-A1 | Piperazine derivatives, their preparation and uses in therapy (5ht1b receptor activity) | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-07-08 | — | — | US | disclosed |
| US-6747030-B1 | CIS-6-(3,5-DIMETHYLPIPERAZIN-1-YL)-5-METHOXY-1-(2'-METHYL-4'-( 5-METHYL-1,2,4-OXADIAZOL-3-YL)BIPHENYL-4-CARBONYL)INDOLINE, ITS HYDROCHLORIDE SALT, OR ANOTHER PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; ANTIDEPRESSANTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-06-08 | — | — | US | disclosed |
| EP-1216239-B1 | PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-02-11 | — | — | EP | disclosed |
| EP-1216239-A1 | PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2002-06-26 | — | — | EP | disclosed |
| US-6235731-B1 | REDUCING BLOOD LIPIDS, SUGARS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| WO-2001023374-A1 | PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-04-05 | — | — | WO | disclosed |
| EP-0915888-A1 | FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS | Takeda Chemical Industries, Ltd. (JP) | 1999-05-19 | — | — | EP | disclosed |
| WO-1997040051-A1 | FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054850-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | UTS2R, GPR17, NTSR2 | HTR2C 169/4885CHRM2 712/4885CHRM4 1210/4885 |
| US-20040132720-A1 | Piperazine derivatives, their preparation and uses in therapy (5ht1b receptor activity) | SIGMAR1, HTR6, OPRL1 | HTR2C 12/4885CHRM2 138/4885CHRM4 245/4885 |
| US-20040176388-A1 | Piperazine derivatives as 5-HT1B antagonists | HTR1B, HTR2B, HTR2A | HTR2C 10/4885CHRM2 312/4885CHRM4 508/4885 |
| US-20160159832-A1 | SILYLALKYLOXYARYL COMPOUNDS AND METHODS FOR TREATING CANCER | BCL3, MYLK2, BCL2L13 | HTR2C 2347/4885CHRM2 2887/4885CHRM4 3622/4885 |
| US-20110275648-A1 | FLURBIPROFEN ANALOGS AND METHODS OF USE IN TREATING CANCER | HCAR1, AADAC, AADAT | HTR2C 878/4885CHRM2 1731/4885CHRM4 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.